Drug Trial Radar · NCT07951411
Evaluating the Efficacy and Safety of SAL0167 Tablets at Different Doses in Participants With Hyperlipidemia.
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Dec 31, 2026
Primary completion
Jul 30, 2027
Study completion Jul 30, 2027
Sponsor
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, multicenter phase II clinical trial. The purpose of this study is to evaluate the efficacy and safety of SAL0167, an oral PCSK9 inhibitor, in lowering low-density lipoprotein cholesterol (LDL-C) in participants with hyperlipidemia. Participants will be randomized 1:1:1:1 to receive low-dose SAL0167, medium-dose SAL0167, high-dose SAL0167, or placebo for a treatment period of 8 weeks.
Conditions
- Hyperlipidemia
Interventions
SAL0167 Dose 1Drug
SAL0167 Dose 1
SAL0167 Dose 2Drug
SAL0167 Dose 2
SAL0167 Dose 3Drug
SAL0167 Dose 3
placeboDrug
placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)Time frame: to Week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.